NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. NeoPhore’s drug target rationale is highly validated by genetic evidence in cancer patients and cellular models.

NeoPhore was created to exploit the first of the pipeline of selective, patient-specific drugs generated by the PhoreMost platform.